## 29N-am01

Characterization of cubosomes loaded with water insoluble drug SN38 ○Abdul-Hackam RANNEH<sup>1</sup>, 岩尾 康範<sup>1</sup>, 野口 修治<sup>1</sup>, 岡 俊彦<sup>2</sup>, 板井 茂<sup>1</sup>(<sup>1</sup>静 岡県大院薬,<sup>2</sup>静岡大理)

[Purpose] SN38, a very potent anticancer drug, has low water solubility 7  $\mu$ g/mL and is prone to hydrolysis under physiological conditions rendering it biologically inactive. To overcome these problems, we tried to prepare cubosomes due to their sophisticated lipid bilayer-based inner structure.

[Method] Mixtures, with various ratios, of phytantriol (cubic phase forming amphiphile), didodecyldimethylammonium bromide (DDAB, co-lipid), SN38 and Poloxamer 407 (steric stabilizer) were homogeneously mixed and then probe-sonicated. Inner structure was characterized using small angle X-ray scattering. Particle size and zeta potential were measured using dynamic and electrophoretic light scattering, respectively. Drug concentration was determined by reversed-phase HPLC. Gel filtration was used to confirm encapsulation efficiency (EE). Drug stability test was carried out at 25°C in a PBS medium.

[Results and Discussion] Inner structures of all cubosomes were of the cubic space group *Pn3m*. Empty cubosomes had a median diameter of 93 nm, zeta potential of 3.93 mV and a polydipersity index (PDI) value of 0.054, indicating a monodispersion. SN38-loaded cubosomes had a median diameter of 120 nm and a zeta potential value of 8.38 mV and a PDI value of 0.18 which also can be considered as a monodispersion, for freshly prepared formulations. Loading SN38 into cubosome made it possible to increase its solubility up to 110 µg/mL, which is almost 16-fold of the free drug water solubility. EE was found to be 93.7%. Encapsulated SN38 was stable as only 10% was hydrolyzed into the inactive form after 24 h, whereas more than 90% of the free drug was hydrolyzed within 3 h. After 24 h period at 25° C in a PBS medium, median diameter was still less than 150 nm, which is within the range of passive targeting for future *in vivo* anticancer application.